Anavex Obtains U.S. Patent on Combinations of Anavex 2-73 and Donepezil to Protect Nerve Cells

Anavex Obtains U.S. Patent on Combinations of Anavex 2-73 and Donepezil to Protect Nerve Cells
The U.S. Patent and Trademark Office has granted Anavex Life Sciences a patent covering nerve protection treatments that combine Anavex 2-73 and donepezil. The patent is titled "ANAVEX 2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection." It offers Anavex exclusive rights to the approach through 2033, the company said in a press release. Donepezil is the medical constituent of Aricept, which is approved for the treatment of Alzheimer’s disease. Anavex 2-73 targets a brain receptor called sigma-1 as well as muscarinic receptors. Studies show that the sigma
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *